1. Introduction

In 2012, an estimated 790,000 women in the United States were diagnosed with cancer, of whom 10% were of reproductive age (American Cancer Society, 2012; Schover, 2005). Improvements in screening have increased the proportion of fertile women diagnosed with cancer. [NIH surveillance] (National Institute of Health, 2010; Society of Family Planning, 2012) Addressing the possibility of future pregnancy is an important aspect of survivorship and quality of life for patients undergoing cancer treatment, and several ways to preserve fertility during cancer therapy have been developed and studied (Letourneau et al., 2012; McLaren and Bates, 2012). As background, 49% of pregnancies in the United States are unintended and unplanned (The Alan Guttmacher Institute [AGI], 2013). Patients with medical co-morbidities, including those undergoing cancer treatment and/or surveillance, are among this group. It is estimated the incidence of malignancy and pregnancy is approximately 1:1000 (Pavlidis, 2002; Smith et al., 2003). Although rare, pregnancy in the setting of cancer treatment may create clinical and ethical dilemmas, with potential increased risks for both the patient and gestation. These dilemmas are further compounded when a pregnancy in this setting is unplanned.

Among women who have undergone or are currently undergoing cancer treatment, there is limited data regarding the rate of unintended pregnancy or patients’ impression of fertility. It has been previously reported that childhood cancer survivors between 15 and 30 years old were more likely to terminate a pregnancy compared to age-matched controls (Green et al., 2002). A survey of female cancer patients revealed that 55% believed that they could not become pregnant after cancer treatment, and 45% of the same group denied using any contraception that 55% believed that they could not become pregnant after cancer treatment, and 45% of the same group denied using any contraception.
McLaren and Bates, 2012). For this reason, we conducted a survey of current members of the Society of Gynecologic Oncology (SGO) regarding reproductive counseling, practices, and experience with unplanned pregnancy in this population.
administering contraception and/or were less likely to report referring to reproductive endocrinology.

In contrast, those who reported providing counseling on both fertility and contraception were more likely to be female and/or an attending. They also were more likely to be older; although that difference was not statistically significant. Providers who reported sometimes or always providing counseling on both reproductive topics were also more likely to report providing or administering contraception and/or to refer to reproductive endocrinology. There were no notable differences in reproductive counseling status by U.S. region, type of practice, or number of years in practice.

Next, we examined what factors were associated with an increased odds of reporting providing fertility counseling sometimes or always (Table 3). After adjustment for gender, we found that the odds of reporting providing fertility counseling were nearly three times higher among attending physicians as compared to fellows [AOR = 2.72; 95% CI = (1.44, 5.12)]. In examining contraceptive counseling (Table 4), we found that the odds of reporting providing contraceptive counseling was 2.8 times higher in women as compared to men and was 4.91 times higher in individuals age 50+ compared to those <40 after adjustment for level of practice.

Overall, 81.7% of providers reported counseling, prescribing, or administering contraception to their patients. Among these individuals, the most frequently cited contraceptive that providers reported addressing with their patients included: oral contraceptive pills (81%), intrauterine devices (73%), depot medroxyprogesterone acetate (DPMA) injections (56%), and contraceptive implants (21%). The most frequently cited contraceptives that providers reported prescribing or administering included: oral contraceptive pills (80%), intrauterine devices (62%), DPMA injections (48%), and contraceptive implants (9%). The reported prevalence of unplanned pregnancy among the surveyed providers' patients was relatively rare, perhaps because it is not routinely addressed.

Table 2
Selected characteristics by reproductive counseling status.

| Factor                      | Neither (n = 73) | Fertility only (n = 46) | Contraception only (n = 38) | Both (n = 83) |
|-----------------------------|------------------|-------------------------|-----------------------------|--------------|
| Age (years)                 |                  |                         |                             |              |
| < 40                        | 56.9% (41)       | 55.6% (25)              | 39.5% (15)                  | 35.4% (28)   |
| 40-49                       | 25.0% (18)       | 26.7% (12)              | 21.1% (8)                   | 27.9% (22)   |
| 50-59                       | 8.3% (6)         | 11.1% (5)               | 29.0% (11)                  | 21.5% (17)   |
| 60+                         | 9.7% (7)         | 6.7% (3)                | 10.5% (4)                   | 15.2% (12)   |
| Gender†                     |                  |                         |                             |              |
| Male                        | 54.2% (39)       | 40.0% (18)              | 24.3% (9)                   | 48.8% (40)   |
| Female                      | 45.8% (33)       | 60.0% (27)              | 75.7% (28)                  | 51.2% (42)   |
| Region                      |                  |                         |                             |              |
| Northeast                   | 30.0% (21)       | 41.3% (19)              | 29.0% (11)                  | 33.7% (28)   |
| Southeast                   | 22.5% (16)       | 17.4% (8)               | 18.4% (7)                   | 22.9% (19)   |
| Midwest                     | 21.1% (15)       | 13.0% (6)               | 31.6% (12)                  | 15.7% (13)   |
| West                        | 8.5% (6)         | 21.7% (10)              | 15.8% (6)                   | 15.7% (13)   |
| Southwest                   | 18.3% (13)       | 6.5% (3)                | 5.3% (2)                    | 12.1% (10)   |
| Level of practice†          |                  |                         |                             |              |
| Fellow                      | 41.7% (30)       | 19.6% (9)               | 23.7% (9)                   | 14.5% (12)   |
| Attending                   | 58.3% (42)       | 80.4% (37)              | 76.3% (29)                  | 85.5% (71)   |
| Medical specialty*          |                  |                         |                             |              |
| Gyn Onc                     | 100.0% (73)      | 100.0% (46)             | 97.4% (37)                  | 95.2% (79)   |
| Med Onc                     | 0% (0)           | 0% (0)                  | 2.6% (1)                    | 2.4% (2)     |
| General GYN                 | 0% (0)           | 0% (0)                  | 0% (0)                      | 2.4% (2)     |
| Type of practice             |                  |                         |                             |              |
| Private                     | 7.4% (5)         | 13.0% (6)               | 13.5% (5)                   | 11.0% (9)    |
| Academic                    | 78.0% (53)       | 67.4% (31)              | 64.9% (24)                  | 61.0% (50)   |
| Community                   | 14.7% (10)       | 19.6% (9)               | 21.6% (8)                   | 28.0% (23)   |
| Years in practice           |                  |                         |                             |              |
| 1–5                         | 53.4% (39)       | 54.4% (25)              | 36.9% (14)                  | 36.6% (30)   |
| 6–9                         | 12.3% (9)        | 17.4% (8)               | 15.8% (6)                   | 8.5% (7)     |
| 10–15                       | 15.1% (11)       | 13.0% (6)               | 5.3% (2)                    | 13.4% (11)   |
| 16–20                       | 6.9% (5)         | 4.4% (2)                | 10.5% (4)                   | 11.0% (9)    |
| 21+                         | 12.3% (9)        | 10.9% (5)               | 31.6% (12)                  | 30.5% (25)   |
| Prescribe/administer contraception† |             |                         |                             |              |
| Yes                         | 74.0% (54)       | 71.7% (33)              | 86.8% (33)                  | 91.6% (76)   |
| No                          | 26.0% (19)       | 28.3% (13)              | 13.2% (5)                   | 8.4% (7)     |
| Refer to GYN or family planning? |             |                         |                             |              |
| Yes                         | 64.4% (47)       | 69.6% (32)              | 57.9% (22)                  | 54.9% (45)   |
| No                          | 35.6% (26)       | 30.4% (14)              | 42.1% (16)                  | 45.1% (47)   |
| Refer to REI†               |                  |                         |                             |              |
| Yes                         | 74.0% (54)       | 89.1% (41)              | 89.5% (34)                  | 92.8% (77)   |
| No                          | 26.0% (19)       | 10.9% (5)               | 10.5% (4)                   | 7.2% (6)     |
| Do you feel patients recognize unplanned pregnancy risk? |       |                         |                             |              |
| Yes                         | 44.4% (32)       | 58.7% (27)              | 60.5% (23)                  | 62.7% (52)   |
| No                          | 8.3% (6)         | 6.5% (3)                | 5.3% (2)                    | 1.2% (1)     |
| Sometimes                   | 47.2% (34)       | 34.8% (16)              | 34.2% (13)                  | 36.1% (30)   |
| Do you think unplanned pregnancy is a problem in this population? | |                             |                             |              |
| Yes                         | 81.9% (59)       | 78.3% (36)              | 73.7% (28)                  | 87.8% (72)   |
| No                          | 18.1% (13)       | 21.7% (10)              | 26.3% (1)                   | 12.2% (10)   |

* GynOnc denotes gynecologic oncology, MedOnc denotes medical oncology, general GYN denotes general gynecology, and REI denotes reproductive endocrinology and infertility.
† p < 0.05.
Most providers (95%) reported 0–5 unplanned pregnancies among their patients in the last 5 years, with only 3 providers (1%) reporting more than ten unplanned pregnancies.

4. Discussion

Unplanned pregnancy in the setting of cancer treatment or surveillance is a complicated issue, and may create clinical and ethical dilemmas for the patient, partner, family, and treatment team. The majority of survey respondents appropriately acknowledged the risk of unplanned pregnancy among gynecologic cancer patients maintaining fertility potential. However, only half reported addressing contraception planning in this population on a consistent basis (52% “always” addressing contraception, versus 35% “sometimes”). Regarding the consistency with which contraception is addressed, these findings are consistent with a retrospective chart review completed at our institution where 45% of initial consultations documented a contraception plan in fertile patients of reproductive age, and 32% of follow-up visits for those that maintained fertility potential after cancer treatment (Crafton et al., 2016).

Depending on individual circumstances, contraception planning may be more important than fertility sparing treatment options. Patient’s reproductive goals should be determined in order to tailor fertility-sparing treatment, when possible, versus contraception planning. Unfortunately, only half of respondents reported always addressing fertility concerns with patients in this population. This is consistent with the fact 50% of those surveyed routinely offer referral for preconception counseling for those patients considering fertility preservation options or planned pregnancy. Referral specifically for contraception counseling was reported less frequently, and even fewer reported follow up for plan establishment. Our study was unable to determine which patients or providers relied on the patient’s primary care physician or gynecologist for the establishment of a contraception plan.

The incidence of unplanned pregnancy in this population is reportedly rare, with 96% of responding physicians experiencing <5 unplanned pregnancies in the previous five years. This may be under-reported, as oncologists may be unaware of pregnancies, especially during disease surveillance. Despite the rarity, eleven providers report experiencing an estimated 6–20 unplanned pregnancies during that time same. The opportunity to avoid even a fraction of those merits further acknowledgement of this topic.

It is reassuring that the large majority of providers reportedly counsel for and administer contraception methods, including 89% reportedly counseling for the IUD and 77% employing its use. However, it was not specified in this survey if the indication for oral contraceptive pills (OCPs) or an IUD was for contraception planning or cancer therapeutic purposes. Of reported methods, OCPs were the most frequent contraception method both counseled for and administered. When compared to implantable methods, both the IUD and subdermal implant, both actual and ideal use of OCPs have a higher failure rate, and therefore more reliable methods should be considered first, barring contraindications (Centers for Disease Control and Prevention, 2010).

Given our findings that the attending cohort was more likely to provide contraception and/or fertility counseling sometimes or always compared to the fellow respondents (Tables 2, 3), there seems to be an opportunity to improve education for fellows regarding fertility preservation options for these patients.

As seen in other survey-based studies, the primary limitation of the study is the modest response rate, despite multiple recruitment attempts and limiting the length of the survey (Cunningham et al., 2015). Given the response rate, the potential for selection and survey content bias (i.e., only those who were interested in the topic responded) is present thus the results may have limited external validity. However, as aforementioned, our respondent cohort is comparable to the data published in the 2015 Society of Gynecologic Oncology: State of the subspecialty. Inclusion of both fellows in training and retired members also limits the external validity of the survey regarding current members, but we felt inclusions of these populations were interesting and important in order to compare potential generational differences. Many gynecologic cancer diagnoses are made in peri-menopausal or postmenopausal women; therefore assessing what portion of a provider’s practice is of reproductive age could aid discussion and interpretation of results. Likewise, as the type of cancer and respective treatment options may change the potential for or etiology of infertility, assessing providers’ experience with specific disease processes, such as gestational trophoblastic neoplasia, also could aid discussion, and intervention.

We acknowledge that a contraception plan may not appropriate for all patients undergoing cancer care, especially for who decline fertility sparing treatment, have been previously sterilized, or are actively attempting conception/currently pregnant. However, routine recognition of reproductive goals should be addressed by providers to alleviate potential biases or assumptions regarding patients’ reproductive goals or sexual activity. Previous literature has reported providers’ lack of counseling and patients’ misunderstanding of reproductive potential after cancer treatment, and therefore a patient survey would be as valuable as the provider’s impression we report (Patel et al., 2009; Karaoz et al., 2010). As life expectancy following cancer treatment diagnosis and treatment improves, and quality of life of survivors is emphasized, helping women meet their reproductive goals should remain an important focus. Comprehensive reproductive counseling should be emphasized, including both fertility sparing options and contraception planning, with the ultimate goal of decreasing unplanned pregnancy.

Conflict of Interest Statement

The authors of this manuscript have no conflicts of interests to disclose.
References

American Cancer Society, 2012. American Cancer: Facts and Figures. Vol. 2012. American Cancer Society, Atlanta.

Centers for Disease Control and Prevention, 2010. U.S. medical eligibility criteria for contraceptive use. MMWR 2010; 59 No. RR-4.

Crafton, S., Nekkanti, S., Lynch, C., et al., 2016. Documentation of pregnancy risk assessment and pregnancy among women presenting for gynecologic oncology consultation. Int. J. Gynecol. Cancer 2016 (1), 35–42 (Jan).

Cunningham, C.T., Quan, H., Hemmelgarn, B., et al., 2015. Exploring physician specialist response rates to web-based surveys. BMC Med. Res. Methodol. 15, 32 (Apr 9).

Green, D.M., Whitton, J.A., Stovall, M., et al., 2002. Pregnancy outcomes of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am. J. Obstet. Gynecol. 187, 1070–1080.

Karaoz, B., Aksu, H., Kucuk, M., 2010. A qualitative study of the information needs of premenopausal women with breast cancer in terms of contraception, sexuality, early menopause, and fertility. Int. J. Gynaecol. Obstet. 109, 118–120.

Letourneau, J.K., Ebbel, E.E., Katz, P.P., et al., 2012. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 118 (6), 1710–1717 (Mar 15).

McLaren, J.F., Bates, G.W., 2012. Fertility preservation in women of reproductive age with cancer. Am. J. Obstet. Gynecol. 207 (6), 455–462.

National Institute of Health, 2010. Surveillance epidemiology and end results. Bethesda, MD. Available from: http://seer.cancer.gov/faststats/selections.php#Output.

Patel, A., Sreedevi, M., Malapati, R., et al., 2009. Reproductive health assessment for women with cancer: a pilot study. Am. J. Obstet. Gynecol. 201 (191), e1–e4.

Pavlidis, N., 2002. Coexistence of pregnancy and malignancy. Oncologist 7 (4), 279–287 (Aug).

Schover, L.R., 2005. Sexuality and fertility after cancer. Hematol. Am. Soc. Hematol. Educ. Program 523–527.

Smith, L.H., Danielsen, B., Allen, M.E., Cress, R., 2003. Cancer associated with obstetric delivery: results of linkage with the California cancer registry. Am. J. Obstet. Gynecol. 189 (4), 1128–1135 (Oct).

Society of Family Planning, 2012. Clinical guidelines: cancer and contraception. Contraception 86, 191–198.

The Alan Guttmacher Institute (AGI), 2013. Unintended pregnancy in the United States. AGI, New York.